Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

DEAR: Use of Darolutamide, Enzalutamide and Apalutamide in the Real-world for Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)

NCT05362149 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT05362149
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05362149 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
DEAR: Use of Darolutamide, Enzalutamide and Apalutamide in the Real-world for Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)
Lead sponsor
Bayer
Phase
Observational
Overall status
Completed
Start date
April 4, 2022
Completion date
June 30, 2023
Enrollment
870 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-metastatic castration-resistant prostate cancer